HIV Drugs

Global Market Trajectory & Analytics

MCP-6176

EXECUTIVE ENGAGEMENTS

* Login for a full stack data experience

DATE

APR 2021

TABLES

123

205

EDITION

16

PRICE

USD 5450

CODE

MCP-6176

*Engagement stats are ongoing and dynamic

COMPETITIVE METRICS

	COMPANY	D S N T % *
	Adamis Pharmaceuticals Corporation
	Aphios Corporation
	AstraZeneca PLC
	Aurobindo Pharma Ltd.
	Boehringer Ingelheim International GmbH
	Bristol-Myers Squibb Company
	Cavidi
	Cipla Ltd.
	Cipla Medpro (Pty) Ltd.
	Endo International PLC

SUBMIT

Note: Best viewed in Landscape Mode

RESEARCH MODULES MARKET TRENDS EXECUTIVES

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for HIV Drugs estimated at US$22.8 Billion in the year 2020, is projected to reach a revised size of US$26.8 Billion by 2027, growing at a CAGR of 2.3% over the analysis period 2020-2027. Multi-Class Combination Drugs, one of the segments analyzed in the report, is projected to record a 2.7% CAGR and reach US$9.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Nucleoside Reverse Transcriptase Inhibitors (NRTIs) segment is readjusted to a revised 2.7% CAGR for the next 7-year period.

The HIV Drugs market in the U.S. is estimated at US$6.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.3 Billion by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.5% and 1.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1% CAGR.

In the global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) segment, USA, Canada, Japan, China and Europe will drive the 1.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.6 Billion by the year 2027, while Latin America will expand at a 2.9% CAGR through the analysis period.

SELECT PLAYERS

AbbVie, Inc.; AstraZeneca PLC; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Cipla Ltd.; Daiichi Sankyo Co., Ltd.; Emcure Pharmaceuticals Pvt., Ltd.; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Hetero Drugs Ltd.; Johnson & Johnson; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd.; ViiV Healthcare

SEGMENTS

» Medication Class [Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors, and HIV Integrase Stand Transfer Inhibitors]

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

World Current & Future Analysis for HIV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World Historic Review for HIV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

World Current & Future Analysis for Multi-Class Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World Historic Review for Multi-Class Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Multi-Class Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

World Current & Future Analysis for Nucleoside Reverse Transcriptase Inhibitors (NRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World Historic Review for Nucleoside Reverse Transcriptase Inhibitors (NRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Nucleoside Reverse Transcriptase Inhibitors (NRTIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

World Current & Future Analysis for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World Historic Review for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

World Current & Future Analysis for Protease Inhibitors (PIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World Historic Review for Protease Inhibitors (PIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Protease Inhibitors (PIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

World Current & Future Analysis for Fusion Inhibitors (FI) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World Historic Review for Fusion Inhibitors (FI) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Fusion Inhibitors (FI) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

World Current & Future Analysis for Entry Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World Historic Review for Entry Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for Entry Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

World Current & Future Analysis for HIV Integrase Stand Transfer Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World Historic Review for HIV Integrase Stand Transfer Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

World 15-Year Perspective for HIV Integrase Stand Transfer Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES

USA Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

USA Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

USA 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

CANADA

Canada Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Canada Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Canada 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

JAPAN

Japan Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Japan Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Japan 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

CHINA

China Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

China Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

China 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

EUROPE

Europe Current & Future Analysis for HIV Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Europe Historic Review for HIV Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Europe 15-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Europe Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Europe Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Europe 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

FRANCE

France Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

France Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

France 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

GERMANY

Germany Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Germany Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Germany 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

ITALY

Italy Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Italy Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Italy 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

UNITED KINGDOM

UK Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

UK Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

UK 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

SPAIN

Spain Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Spain Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Spain 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

RUSSIA

Russia Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Russia Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Russia 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

REST OF EUROPE

Rest of Europe Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of Europe Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Rest of Europe 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

ASIA-PACIFIC

Asia-Pacific Current & Future Analysis for HIV Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Asia-Pacific Historic Review for HIV Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Asia-Pacific 15-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027

Asia-Pacific Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Asia-Pacific Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Asia-Pacific 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

AUSTRALIA

Australia Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Australia Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Australia 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

INDIA

India Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

India Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

India 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

SOUTH KOREA

South Korea Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

South Korea Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

South Korea 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

REST OF ASIA-PACIFIC

Rest of Asia-Pacific Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of Asia-Pacific Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

LATIN AMERICA

Latin America Current & Future Analysis for HIV Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Latin America Historic Review for HIV Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Latin America 15-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027

Latin America Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Latin America Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Latin America 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

ARGENTINA

Argentina Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Argentina Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Argentina 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

BRAZIL

Brazil Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Brazil Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Brazil 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

MEXICO

Mexico Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Mexico Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Mexico 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

REST OF LATIN AMERICA

Rest of Latin America Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of Latin America Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Rest of Latin America 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

MIDDLE EAST

Middle East Current & Future Analysis for HIV Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Middle East Historic Review for HIV Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Middle East 15-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027

Middle East Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Middle East Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Middle East 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

IRAN

Iran Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Iran Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Iran 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

ISRAEL

Israel Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Israel Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Israel 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

SAUDI ARABIA

Saudi Arabia Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Saudi Arabia Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Saudi Arabia 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

UNITED ARAB EMIRATES

UAE Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

UAE Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

UAE 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

REST OF MIDDLE EAST

Rest of Middle East Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of Middle East Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Rest of Middle East 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

AFRICA

Africa Current & Future Analysis for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Africa Historic Review for HIV Drugs by Medication Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Africa 15-Year Perspective for HIV Drugs by Medication Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors and HIV Integrase Stand Transfer Inhibitors for the Years 2012, 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 52

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

HIV Drugs

Global Market Trajectory & Analytics

MCP-6176

EXECUTIVE ENGAGEMENTS

POOL

INTERACTIONS

PARTICIPANTS

VALIDATIONS

COMPANIES

* Login for a full stack data experience

DATE

APR 2021

TABLES

123

PAGES

205

EDITION

16

PRICE

USD 5450

CODE

MCP-6176

COMPETITIVE METRICS

COMPANY

% *

Adamis Pharmaceuticals Corporation

Aphios Corporation

AstraZeneca PLC

Aurobindo Pharma Ltd.

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Cavidi

Cipla Ltd.

Cipla Medpro (Pty) Ltd.

Endo International PLC

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

GLOBAL EXPERT PANEL

HIGHLIGHTS & REPORT INDEX

SELECT PLAYERS

SEGMENTS

GEOGRAPHIES

TABLE OF CONTENTS

PREVIEW REPORT

DIFFERENTIATORS

WHAT SETS US APART

FULL STACK DATA ACCESS